BAVA Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.162.90 |
| 52 Week High | kr.222.00 |
| 52 Week Low | kr.125.55 |
| Beta | 1.33 |
| 1 Month Change | 8.24% |
| 3 Month Change | 4.12% |
| 1 Year Change | -21.80% |
| 3 Year Change | -37.35% |
| 5 Year Change | 19.82% |
| Change since IPO | -36.12% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09
Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Feb 26Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry
Jan 03Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 10Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly
Nov 15Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Aug 17Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 19Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?
Jan 03Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?
Sep 15Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic
Jul 24Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts
Jun 14Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)
May 31Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?
May 06Bavarian Nordic A/S (CPH:BAVA) Analysts Just Cut Their EPS Forecasts Substantially
Mar 13Shareholder Returns
| BAVA | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | 7.2% | 4.0% | 2.1% |
| 1Y | -21.8% | -15.6% | 24.5% |
Return vs Industry: BAVA underperformed the Danish Biotechs industry which returned -11.1% over the past year.
Return vs Market: BAVA underperformed the Danish Market which returned 25.7% over the past year.
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in DK Market | 9.9% |
| 10% least volatile stocks in DK Market | 2.8% |
Stable Share Price: BAVA has not had significant price volatility in the past 3 months.
Volatility Over Time: BAVA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,379 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | kr.12.70b |
| Earnings (TTM) | kr.1.48b |
| Revenue (TTM) | kr.7.06b |
8.6x
P/E Ratio1.8x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | kr.7.06b |
| Cost of Revenue | kr.1.90b |
| Gross Profit | kr.5.16b |
| Other Expenses | kr.3.69b |
| Earnings | kr.1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | 18.93 |
| Gross Margin | 73.07% |
| Net Profit Margin | 20.89% |
| Debt/Equity Ratio | 0.2% |
How did BAVA perform over the long term?
See historical performance and comparison